Metro Nashville intends to award up to 25 pallet shelters to community partners
NASHVILLE, Tenn. (WKRN) — Metro Nashville plans to distribute pallet shelters for use as temporary housing to community partners.
On Wednesday, the Mayor's Office published a request for proposals from community partners and intends to distribute up to 25 pallet shelter units to community-based organizations. Those pallet shelters can then be used as temporary housing and are meant to offer safe, private spaces for people who cannot easily access group shelters.
MARCH | VIDEO: Federal funding cuts put housing pods plan in jeopardy
According to the request for proposals, the pallet shelters are equipped with beds, LED lighting and locking doors as well as key safety features like smoke and carbon monoxide detectors.
These pallet shelters have a history. During the COVID-19 pandemic, Nashville purchased housing pods for those who needed homes. In 2023, Metro Councilmember Erin Evans passed a resolution calling for the pods to be used as transitional housing. The state ultimately granted Nashville permission last October.
'Eliminating the barriers to use our pallet shelters as a temporary housing option has been a collaborative effort across many Metro stakeholders including Metro Department of Public Health, Office of Homeless Services, Office of Emergency Management and Metro Codes,' Evans said. 'I appreciate Mayor O'Connell's support in offering these shelters to community organizations with this [request for proposals].'
In February, Nashville Mayor Freddie O'Connell announced that two people who had been working on the plan were laid off due to federal funding cuts. Despite that announcement, the Mayor's Office officially opened the call for proposals this week.
'These shelters are temporary housing solutions for our most vulnerable neighbors who need to be housed and connected with supportive services,' O'Connell said. 'I'm grateful for the work of the working group that has facilitated the repurposing of these shelters from infectious disease aids to temporary emergency housing options.'
OCTOBER 2024 | State approves for COVID-19 response pods to be used as transitional housing in Nashville
Metro is seeking proposals from nonprofits and other community partners that can make sure the pallet shelters are properly installed and maintained as well as partners who can help provide residents with services like toilet and shower facilities. Also included in the scope of work is the coordination of on-site support services and reporting shelter use information.
'We are eager to deploy the pallet shelters,' April Calvin, Director of the Office of Homeless Services, said. 'It's going to take all creative solutions to address the need.'
According to the request for proposals, a concept paper is due by June 4 and the full proposal is due by noon on June 20.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Zion Williamson accused of rape in bombshell lawsuit
Pelicans star Zion Williamson is being accused of rape by a woman claiming to be his ex-girlfriend. In a bombshell lawsuit filed Thursday in Los Angeles Superior Court and obtained by The Post, the woman, identified as Jane Doe, alleges Williamson raped her twice in 2020. In one instance, Doe claimed Williamson, 24, arrived to the Beverly Hills home he purportedly rented while training during COVID on Nov. 23, 2020 and demanded sex. According to Doe, Williamson called her 'stuck up' and a 'bitch,' and when she refused to engage in sex, the 6-foot-6, 280-pound power forward 'pinned Plaintiff down on the bed with her hands behind her back and raped her.' Williamson is alleged to have taken her phone and choked her for 'talking too much' afterward. A second claim of rape occurred the following month, in which Doe spoke of potentially visiting a friend, leading Williamson to have allegedly 'picked her up, threw her down to the ground, and pinned her shoulders down so she could not move,' and then he reputedly 'violently raped Plaintiff in multiple ways.' She says he then took her phone and computer so she could not 'contact anyone to secure a ride elsewhere, report the assault, or seek medical care.' ESPN reported the accuser is seeking 'anywhere from $18 million to $50 million.' In a statement provided to The Post, Williamson denied the allegations through his legal reps. 'We take these allegations with the utmost seriousness, and we unequivocally deny them,' his reps said. 'The allegations contained in the complaint are categorically false and reckless. This is the plaintiff's third set of attorneys. This appears to be an attempt to exploit a professional athlete driven by a financial motive rather than any legitimate grievance.' Williamson acknowledged a consensual, casual relationship with Doe, and that she only began demanding 'millions of dollars' after their time together ended. He intends to file a counterclaim against Doe and will seek 'significant damages for this defamatory lawsuit.' 'While these allegations are false, we recognize the seriousness of the claims and welcome the opportunity to prove the truth in court,' his reps said. 'We are confident that the legal process will expose the truth and fully vindicate Mr. Williamson.' Doe's suit alleges a pattern of 'abusive, controlling, and threatening behavior toward Plaintiff' that also occurred in Louisiana and several other states. Williamson is also accused of threatening to have his security guard shoot Doe 'in the head while the security guard was present and carrying a loaded firearm multiple times in Louisiana between 2020 and 2023,' and 'threatening to have his paid security guard kill Plaintiff's parents, after informing Plaintiff that he knows their home address multiple times in Louisiana between 2020 and 2023.' 'Our client is very adamant about this — it's not her desire or our desire to litigate this case in the press,' Doe's attorney, Sam Taylor with the Lanier Law Firm, told The Post on Friday. 'It's a very serious case, as reflected in the allegations. Our client looks forward to her day in court where she can go and explain to a jury what happened to her, the things she endured for this defendant and getting justice.' Doe claims to have been in a 'dating relationship' with Williamson beginning around 2018 while he was a freshman at Duke, and the relationship continued through June 2023. Williamson went on to be the first overall pick by New Orleans in the 2019 NBA Draft. Despite an injury-marred start to his career, he made the All-Rookie team in 2020 and has twice been an All-Star in five seasons, all with the Pelicans. Williamson has made headlines over his personal life on a numerous occasions. In April, Williamson was dragged into a home invasion incident involving the mother of his child, Ahkeema Love, 31, who was arrested for attacking a romantic rival. Love was charged with home invasion, aggravated battery and stalking after she broke into an unidentified woman's residence and 'grabbed the victim's hair and struck the victim with keys clenched in her fist,' Kenner police said in a probable cause affidavit, per NBC News. Williamson was not named in the affidavit. Love was served an order of protection as part of her custody release following a bond hearing, according to court records. In 2023, adult film star Moriah Mills claimed she had an intimate relationship with the former No. 1 overall pick, and threatened to release alleged sex tapes of the two. In March, Love revealed she is pregnant and celebrating 'another addition to our family' in an Instagram post. She did not name the child's father. Love and Williamson welcomed a daughter in 2023.
Yahoo
2 hours ago
- Yahoo
FDA OKs new COVID-19 vaccine for 65 and older, others with conditions
May 31 (UPI) -- The Food and Drug Administration has approved Moderna's new COVID-19 vaccine, days after the federal government tightened vaccine standards for the virus. The FDA announced Friday that mNEXSPIKE can be given to adults 65 and older and those 12 to 64 with at least one underlying condition that could put them at risk of severe infection. Recipients also must have been previously vaccinated for COVID-19. The company, headquartered in Cambridge, Mass., said Saturday it expects to have the vaccine available for the 2025-2026 respiratory virus season. Moderna also produces Spikevax for COVID-19, and mRESVIA for the respiratory syncytial virus, or RSV. "The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19," Stéphane Bancel, chief executive officer of Moderna, said. "COVID-19 remains a serious public health threat, with more than 47,000 Americans dying from the virus last year alone. We appreciate the FDA's timely review and thank the entire Moderna team for their hard work and continued commitment to public health." STAT reported the next-generation COVID-19 vaccine uses a refined target to generate antibodies against the SARS-CoV-2 virus. The dose is one-fifth the doage used in Spikevax, the current vaccine. Moderna conducted a randomized, observer-blind Phase 3 clinical trial of approximately 11,400 participants aged 12 years and older to test the mRNA-1283. The primary efficacy was to demonstrate the vaccine efficacy against COVID-19 starting 14 days after mNEXSPIKE compared with Spikevax, Moderna's updated COVID-19 vaccine approved on Sept. 6, 2024. The new vaccine showed a 9.3% higher relative vaccine efficacy than the mRNA-1273 in individuals aged 12 years and older. It was 13.5% better in adults aged 65 and older. In the Phase 3 trial, the most common side effects were injection site pain, fatigue, headache and myalgia. The company said there is a very small chance that mNEXSPIKE could cause a severe allergic reaction, usually within a few minutes to 1 hour after getting a dose of mNEXSPIKE. Myocarditis, which is inflammation of the heart muscle, and pericarditis, which is inflammation of the lining outside the heart, have occurred in some people who have received mRNA COVID-19 vaccines, Moderna said. Of those with problems, they are among males12 through 24. The FDA has asked Moderna to conduct post-marketing studies to continue to evaluate the safety and effectiveness of the product. This includes a study on the outcomes of pregnant people and their babies when the vaccine was administered during pregnancy. The study is to be submitted by the end of 2032. Pfizer was the first COVID-19 vaccine to receive emergency approval in December 2020 and Moderna was followed one week later. The first COVID-19 cases were reported in the United States in January 2020. The FDA first granted Pfizer-BioNTech full COVID-19 approval for those 12 and older in August 2021 and Moderna in January 2022. They remain available under emergency use authorization for children as young as 6 months. On Friday, the Centers for Disease Control and Prevention said children without underlying health conditions "may receive" a COVID-19 vaccine, contradicting a directive by Health and Human Services Secretary Robert F. Kennedy Jr. earlier in the week. The CDC updated the childhood immunization schedule published late Thursday. Kennedy, who said the agency would stop recommending the shots for healthy children, noted the guidelines would be changed. The new schedule also requires health insurance companies, Medicare and Medicaid plans to continue to cover the vaccines for children. COVID-19 shots during pregnancy are listed as "No Guidance/Not Applicable," where they were previously recommended for all pregnant adults. Earlier this month, the FDA approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay. The agency approved the vaccine only for people 65 and older and those 12 and older with at least one underlying condition at a higher risk of severe illness. This week, HHS notified Moderna that it was canceling contracts worth $766 million to develop, test and license vaccines for flu subtypes that could trigger future pandemics, including the dangerous H5N1 bird flu virus. The first COVID-19 case was reported in the United States on Jan. 20, 2020. About 23% of U.S. adults are estimated to be up to date with the vaccine, according to the CDC through April. For children 6 months and up to 18, it is an estimated 13.%, the CDC reported.
Yahoo
2 hours ago
- Yahoo
FDA clears Moderna's new COVID vaccine, but with limits
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. The Food and Drug Administration has granted an approval to Moderna's next-generation COVID-19 vaccine, but with limits that will restrict use to older adults and people with preexisting health conditions. The OK is the first since agency leadership rolled out new guidelines for COVID shot approvals. The new vaccine, which Moderna will sell as mNexspike, is cleared for healthy adults 65 years and older and for individuals aged between 12 years and 64 years with one or more underlying 'risk factors,' the company said Saturday. Moderna CEO Stéphane Bancel called the shot an 'important new tool' to protect people from COVID, noting in a statement that more than 47,000 people in the U.S. died from the disease last year. The FDA based its decision on data from a Phase 3 study that pitted mNexspike against Spikevax, Moderna's original vaccine which is cleared for broad use. Results found mNexspike was 'non-inferior' to Spikevax overall and, in people older than 12 years, slightly more effective on a relative basis. Moderna expects to make mNexspike, which is currently targeted to the JN.1 coronavirus variant, available beginning in the fall. The FDA granted its approval by a May 31 deadline it had set, despite worries that recent moves by Trump administration officials might jeopardize the shot. In May, FDA Commissioner Martin Makary and top vaccine official Vinay Prasad said the agency would require placebo-controlled trials before it cleared any new COVID shots in healthy children and adults. Previously, the FDA has accepted comparative immune data for some decisions, such as for boosters. More recently, Health and Human Services Secretary Robert F. Kennedy Jr. said the Centers for Disease Control and Prevention would remove COVID shots from the recommended immunization schedules for pregnant women and healthy children. The CDC has since confused that messaging with a notice indicating the shots remain an option for children. MNexspike's approval is similar to what the FDA recently granted Novavax's protein-based shot Nuvaxovid. That vaccine is also cleared for older adults and those at high risk, while the company is required to conduct an additional study. Messenger RNA shots like Moderna's and Pfizer's Cominarty have appeared to be under higher scrutiny, however. Kennedy has previous questioned the technology, and HHS recently canceled a lucrative contract with Moderna to develop mRNA vaccines for pandemic-prone influenza like bird flu. MRNA shots can be developed and adapted more quickly, traits that allowed Pfizer and Moderna to quickly deliver safe and effective vaccines early on in the pandemic. In a note to clients, Jefferies analyst Michael Yee said the on-time approval is an 'incremental positive' for Moderna. It shows FDA leaders are 'still rational so long as the data packages show good efficacy and is well conducted.' However, there's still some risk Moderna doesn't hit its sales guidance, he added, as vaccination rates remain low. Advisers to the CDC are set to meet in late June to discuss COVID vaccine use recommendations for the coming fall and winter seasons.
